Products for Research Use Only
RegisterLogin

Selonsertib

CAT: 0804-HY-18938-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18938-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.
CAS Number
1448428-04-3
Product Name Alternative
GS-4997
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; MAP3K
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Selonsertib.html
Purity
99.05
Solubility
DMSO : 66.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=NC(C2=NN=CN2C(C)C)=CC=C1)C3=CC(N4C=C(C5CC5)N=C4)=C(C)C=C3F
Molecular Formula
C24H24FN7O
Molecular Weight
445.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Lanier M, et al. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. ACS Med Chem Lett. 2017 Feb 8;8 (3) :316-320.|[2]Lin JH, et al. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129 (1) :29-33.|[3]Loomba R, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2trial. Hepatology. 2018 Feb;67 (2) :549-559.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
MAP3K5/ASK1

Alternative Products

CatalogName
MBS384790-01Selonsertib
A15991-50Selonsertib 50mg
GW0805-5mgSelonsertib Hydrochloride
A15991-500Selonsertib 500mg
A15991-1Selonsertib 1mg
GTR19209453-01Selonsertib HCl
A15991-100Selonsertib 100mg
A15991-10Selonsertib 10mg

Popular Products